A5088560955- Cancer, Lipids, and Metabolism
- Caveolin-1 and cellular processes
- Cancer, Hypoxia, and Metabolism
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Estrogen and related hormone effects
- Pharmacogenetics and Drug Metabolism
- Ferroptosis and cancer prognosis
- Prostate Cancer Treatment and Research
- RNA Research and Splicing
- Immunotherapy and Immune Responses
- RNA and protein synthesis mechanisms
- Protein Degradation and Inhibitors
- Hepatocellular Carcinoma Treatment and Prognosis
- Melanoma and MAPK Pathways
- Retinoids in leukemia and cellular processes
- Ubiquitin and proteasome pathways
- Cancer-related gene regulation
- Drug Transport and Resistance Mechanisms
- Epigenetics and DNA Methylation
- Hormonal Regulation and Hypertension
- Cancer Genomics and Diagnostics
- Cancer Research and Treatments
- PI3K/AKT/mTOR signaling in cancer
University of Tennessee Health Science Center
2021-2023
Baylor College of Medicine
2019-2021
Jawaharlal Nehru University
2014-2018
Gentofte Hospital
2017-2018
University of Copenhagen
2018
Almost half of the patients with metastatic melanoma obtain only short-term or no benefit at all from checkpoint inhibitor (CPI) immunotherapy. In this study, we investigated whether immune system progressing following CPI treatment was able to generate functional tumor-specific responses.Tumor-infiltrating lymphocytes (TILs) were isolated and expanded lesions which progressed during after anti-programmed cell death protein 1 (PD)-1 anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) treatment....
Abstract Prostate cancer (PCa) is dependent on the androgen receptor (AR). Advanced PCa treated with an deprivation therapy-based regimen; tumors develop resistance, although they typically remain AR-dependent. Expression of constitutively active AR variants lacking ligand-binding domain including variant AR-V7 contributes to this resistance. and AR-V7, as transcription factors, regulate many same genes, but also have unique activities. In study, capacity two isoforms splicing was examined....
Abstract Pancreatic ductal adenocarcinoma (PDA) tumors have a highly immunosuppressive desmoplastic tumor microenvironment (TME) where immune checkpoint inhibition (ICI) therapy has been exceptionally ineffective. Transforming growth factor‐β (TGF‐β) receptor activation leads to cancer and cell proliferation phenotype, cytokine production leading progression worse overall survival in PDA patients. We hypothesized that TGF‐β may alter antitumor immunity the TME. Here, we used syngeneic...
Abstract The Pregnane and Xenobiotic Receptor (PXR; NR1I2) is a ligand‐modulated transcription factor that belongs to the nuclear receptor superfamily. It expressed at higher levels primarily in liver intestine as compared several other organs. activated by broad spectrum of xenobiotics endobiotics. primary function PXR regulate expression drug metabolizing enzymes transporters prevent accumulation toxic chemicals body, thereby maintaining body's homeostasis. In this study, we identified C/T...
Constitutive Androstane Receptor (CAR, NR1I3), a member of the nuclear receptor superfamily transcription factors, has emerged as one key regulators drug and xenobiotic metabolism. The unique feature that separates CAR from other members is it remains active in absence ligand further regulated by activators. From its first isolation 1994, number studies related to distribution, characteristics, functions, relation have been conducted place centrally, governing many events body. Human...
Abstract Identifying novel, unique, and personalized molecular targets for patients with pancreatic ductal adenocarcinoma (PDAC) remains the greatest challenge in altering biology of fatal tumors. Bromo- extra-terminal domain (BET) proteins are activated a noncanonical fashion by TGFβ, ubiquitous cytokine PDAC tumor microenvironment (TME). We hypothesized that BET inhibitors (BETi) represent new class drugs attack tumors via novel mechanism. Using combination patient syngeneic murine models,...
<p>Supplementary Figure Legends</p>
<p>Figure S3</p>
<div>Abstract<p>Identifying novel, unique, and personalized molecular targets for patients with pancreatic ductal adenocarcinoma (PDAC) remains the greatest challenge in altering biology of fatal tumors. Bromo- Extra-Terminal domain (BET) proteins are activated a non-canonical fashion by TGF-β, ubiquitous cytokine PDAC tumor microenvironment (TME). We hypothesized that BET inhibitors (BETi) represent new class drugs attack tumors via novel mechanism. Using combination patient...
<p>updated figure S1</p>
<p>Figure s2</p>
<p>Supplementary Figure Legends</p>
<p>Figure S3</p>
<p>Figure s2</p>
<p>updated figure S1</p>
<p>Supplementary Figure Legends</p>